Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy

  1. Kazutoshi ISOBE1,*,
  2. Yoshinobu HATA2,
  3. Susumu SAKAMOTO1,
  4. Yujiro TAKAI1,
  5. Kazutoshi SHIBUYA3,
  6. Sakae HOMMA1

Article first published online: 30 NOV 2009

DOI: 10.1111/j.1440-1843.2009.01666.x

Issue

Respirology

Respirology

Volume 15, Issue 1, pages 88–92, January 2010

Additional Information

How to Cite

ISOBE, K., HATA, Y., SAKAMOTO, S., TAKAI, Y., SHIBUYA, K. and HOMMA, S. (2010), Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology, 15: 88–92. doi: 10.1111/j.1440-1843.2009.01666.x

Author Information

  1. 1

    Departments of Respiratory Medicine,

  2. 2

    Chest Surgery and

  3. 3

    Surgical Pathology, Toho University Omori Medical Center, Tokyo, Japan

*Kazutoshi Isobe, Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan. Email: kazutoshiisobe@aol.com

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 30 NOV 2009
  3. Received 21 January 2009; invited to revise 29 March 2009; revised 27 May 2009; accepted 18 June 2009 (Associate Editor: Jeffery Swigris).

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (134K)

Keywords:

  • acute respiratory deterioration;
  • collagen vascular disease;
  • lung cancer;
  • pulmonary fibrosis;
  • usual interstitial pneumonia

This retrospective study investigated the risk factors for acute respiratory deterioration following anti-cancer therapy in 41 patients with pulmonary fibrosis and lung cancer. Acute respiratory deterioration occurred in 24% of patients following anti-cancer therapy (surgical resection and chemotherapy). Smoking was an independent risk factor for acute respiratory deterioration.

ABSTRACT

Background and objective:  To clarify the clinical characteristics and risk factors for acute respiratory deterioration following anti-cancer therapy in patients with pulmonary fibrosis (PF) and lung cancer.

Methods:  Patients with primary lung cancer and PF were identified by review of medical records. Of the 865 consecutive patients with primary lung cancer who had been treated between June 1999 and September 2007, 53 were diagnosed as having PF. This retrospective study analysed the prevalence of and risk factors for acute respiratory deterioration after treatment of lung cancer in these patients.

Results:  Acute respiratory deterioration was found in 10 (24%) of the 41 patients who received anti-cancer therapy, and six (60%) of these patients died of respiratory failure. The incidence of acute respiratory deterioration was 28% (8/29) after chemotherapy and 16% (2/12) after surgery. Mortality after acute respiratory deterioration was 50% (4/8) among patients with idiopathic PF and 100% (2/2) among the patients with PF associated with rheumatoid arthritis. Logistic regression analysis revealed that a higher smoking index (cigarettes smoked per day × years of smoking) was a significant risk factor for acute respiratory deterioration (odds ratio: 1.002, P = 0.025).

Conclusions:  Patients with lung cancer who have pre-existing PF should be carefully managed because of their high risk for developing acute respiratory deterioration after anti-cancer therapy.

View Full Article (HTML) Get PDF (134K)